Centre National De La Recherche Scientifique

Institut National De La Sante Et De La Recherche Medicale

Université Paris 13

Mymetics Corporation

Assistance Publique-hopitaux De Paris

UniversitÉ De Paris

Pevion Biotech Ltd.

Universite Paris Cité

Morgane Bomsel

Jean-Philippe Wolf

Sylvain Fleury

Rinaldo Zurbriggen

Anne Lombes

Anne LOMBÈS

The present invention relates to the use of a cyclic peptide comprising the tripeptide reproducing a binding site of fertilin beta to the oocyte integrin, for improving cellular energy metabolism. More particularly, the invention concerns the use of a cyclic peptide comprising the tripeptide FEEc for stimulating the energy metabolism of gametes or embryonic cells in the context of medically assisted procreation (MAP) protocols, in particular promoting the in vitro maturation of the oocyte, the fertilization rate and the birth rate.

Use of a cyclic tripeptide for improving cellular energy metabolism

The invention relates to a cyclic peptide increasing the fusiogenic capacity of the oocyte arising from the disintegrin loop of fertilin beta, to a pharmaceutical composition comprising said cyclic peptide and to the use thereof, particularly in order to supplement culture media used to carry out in vitro fertilization.

Peptide increasing fusiogenic capacity of a gamete

The present invention relates to a virosome-like vesicle comprising at least a gp41-derived antigen or an analogue thereof, said gp41-derived antigen being located to the external surface of and/or encapsulated inside said vesicle and being in a convenient configuration for conferring said virosome-like vesicle with an ability to induce an immune response against a gp41 protein or a human immunodeficiency virus (HIV).

Virosome-like vesicles comprising gp41-derived antigens

The present invention deals with a method for therapeutic or prophylactic treatment of HIV, in particular a prophylactic vaccinal method, comprising at least: administering to a patient a first antigen comprising the broadly neutralizing epitopes of the Membrane Proximal Ectodomain Region (MPER) of gp41, and administering to the same patient a second antigen comprising a modified polypeptide comprising three contiguous segments N, L and C represented by the formula N-L-C and comprising: a N-helix region of gp41(N), a C-helix region of gp41(C), and a connecting loop comprising a synthetic linker (L) between the N and C-helices, the linker replacing amino acids 593-617 of gp41, the numbering scheme being based upon the prototypic isolate HIV-1 HxB2 Clade B strain, said polypeptide comprising the calveolin-1 neutralizing and 98.6 D epitopes, but not 2F5 and 4E10 epitopes, not the fusion peptide, the polypeptide having a minimal immunogenic cross-reactivity with human interleukin 2.

Splitting GP41

Growing community of inventors

Paris, France

Morgane Bomsel